Use of COVID-19 Vaccines in the United States
Interim Clinical Considerations
Healthcare providers who administer the Moderna COVID-19 Vaccine (2023-2024 Formula) to individuals ages 6 months through 11 years should ensure the correct volume of the vaccine (0.25 mL) is withdrawn from the vial and administered to the recipient. Discard vial and excess volume after extracting a single dose.
For additional information, see FDA Announcement and Moderna COVID-19 Vaccine (2023-2024 Formula) Healthcare Provider Fact Sheet (fda.gov)
Summary of recent changes (last updated April 4, 2024):
- New guidance on COVID-19 vaccination and pemivibart (Pemgarda™), a monoclonal antibody authorized for COVID-19 pre-exposure prophylaxis in people who are moderately or severely immunocompromised and meet the FDA-authorized conditions for use.
Reference Materials
- COVID-19 Vaccine Product Information (Updated 3/19/2024)
- Interim 2023–2024 COVID-19 Immunization Schedule for Persons 6 Months of Age and Older (Updated 4/03/2024)
- FAQs for the Interim Clinical Considerations (Updated 4/5/2024)
- COVID-19 Vaccination Recommendations Infographic (Updated 3/5/2024)
- COVID-19 Vaccination Recommendations Infographic (Immunocompromised) (Updated 10/13/2023)
Get Email Updates
Receive email updates about this page.
Special Situations and Populations